Home › Funds › Pivotal bioVenture Partners Investment Advisor LLC › OCS

Pivotal bioVenture Partners Investment Advisor LLC position in OCS

OCULIS HOLDING AG · Health Care

Pivotal bioVenture Partners Investment Advisor LLC reported holding 1,658,907 shares of OCS (OCULIS HOLDING AG) in its Q3 2026 13F filing — a position valued at US$15.5M, representing 6.31% of its reported portfolio and ranking #7 among its reported holdings. Pivotal bioVenture Partners Investment Advisor LLC has disclosed OCS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)1.66M sh
Reported value held$15.49M
Portfolio Weight6.31%
First reportedQ3 2023
Last changeAdd
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Pivotal bioVenture Partners Investment Advisor LLC's OCS position evolved

Pivotal bioVenture Partners Investment Advisor LLC first disclosed a stake in OCS in Q3 2023 at 2,218,754 shares (US$24.4M). The position peaked in Q4 2025 at 2,288,658 shares, worth US$45.7M. Across 13 filings, Pivotal bioVenture Partners Investment Advisor LLC increased the stake 3 time(s), trimmed it 5 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 1,658,907 shares valued at US$15.5M — an increase of 152,657 shares quarter over quarter.. Notable position changes include a 32% increase in Q1 2025 (shares rose 2% over the following quarter), a 27% trim in Q1 2026 (shares fell 48% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.22M $24.41M New
Q4 2023 1.89M $21.21M Reduce
Q1 2024 1.60M $19.23M Reduce
Q2 2024 1.60M $19.07M Hold
Q3 2024 1.60M $19.57M Hold
Q4 2024 1.74M $29.54M Add
Q1 2025 2.30M $43.78M Add
Q2 2025 2.30M $44.66M Hold
Q3 2025 2.30M $40.45M Hold
Q4 2025 2.29M $45.70M Reduce
Q1 2026 1.68M $44.68M Reduce
Q2 2026 1.51M $20.89M Reduce
Q3 2026 1.66M $15.49M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About OCS and 13F data

OCS (OCULIS HOLDING AG) is a Health Care company. 66 other funds we track also report a position in OCS — the largest reported positions include EQT Fund Management S.a r.l. (US$64.9M), Gildi - lifeyrissjodur (US$64.3M), Saturn V Capital Management LP (US$9.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding OCS

All OCS fund holders →

FAQ

How long has Pivotal bioVenture Partners Investment Advisor LLC held OCS?

Pivotal bioVenture Partners Investment Advisor LLC has disclosed OCS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Pivotal bioVenture Partners Investment Advisor LLC's current position in OCS?

As of Q3 2026, Pivotal bioVenture Partners Investment Advisor LLC holds 1.66M shares of OCS (OCULIS HOLDING AG), valued at $15.49M, representing 6.31% of its reported portfolio and ranking #7.

Has Pivotal bioVenture Partners Investment Advisor LLC been buying or selling OCS?

In the latest 13F filing (Q3 2026), Pivotal bioVenture Partners Investment Advisor LLC increased its position in OCS. The position peaked in Q4 2025 at 2.29M shares.

Which other funds hold OCS?

Other major institutional holders of OCS include EQT Fund Management S.a r.l., Gildi - lifeyrissjodur, Saturn V Capital Management LP, among 66 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.